Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Gold/Mining/Energy : Gensci Regeneration Sciences Inc. (GNS) -- Ignore unavailable to you. Want to Upgrade?

To: Edward W. Richmond who wrote (194)	8/10/1999 9:57:00 PM
From: Andras	Respond to of 225

Edward, your analysis as far as it goes is fairly straight forward. However, GNS is essentially two companies and the segmented information is I think much more revealing. Three months ended Six months ended June 30 June 30 1999 1998 1999 1998 ---- ---- ---- ---- Segment profit (loss): $ $ $ $ Bioimplants 753,076 (1,631) 1,165,527 (292,092) Biopharmaceuticals (397,766) (568,650) (876,950) (1,076,462) ----------- ----------- ----------- ----------- 355,310 (570,281) 288,577 (1,368,554) It shows that the operating, bioimplants division had a profit of Three months ended in June of about $750,000, whereas the research division, biopharmaceuticals, had a loss of about $400,000. What it shows to me that the operating division is viable and is growing in sales, and that the research arm is a bit of a net drain for now, certainly not unusual for biotech companies. Happy investing, andrew